WASHINGTON - June 4, 2024 – The Biotechnology Innovation Organization (BIO), in partnership with Korn Ferry, today released a new survey assessing diversity, equity, and inclusion (DEI) in the biotechnology industry. The report, “Charting a Path to Inclusive Excellence for Biotechnology Companies,” analyzes the state of DEI in the biotechnology industry, assesses behavioral and structural practices that drive inclusive excellence at companies, and identifies areas to help guide organizations on their DEI journeys.Key findings from the report include:The vast majority (85%) of participating organizations rate DEI as an “Important,” “Very Important,” or “Critical” area of strategic focus.Most biotechnology companies are collecting information related to employee age (90%) and gender (85%) and incorporating it into HR systems, and over two-thirds (69%) are gathering data on race/ethnicity.The top response for DEI efforts (90%) is the ability to foster employee satisfaction and well-being in the workforce. When looking at the future impact of efforts, enabling business strategy increases to 47% 5 years from now.Participating organizations (94%) indicated that there has been no change, moderate, or significant increase in DEI investment over the last two years.Most participating companies (79%) indicate that active partnerships have been formed with diverse educational institutions and community and professional organizations.“The most successful companies are continuing to include DEI into their corporate strategy as a testament to the fact that DEI matters for workplace productivity and retention of the workforce,” said Elizabeth Jeffords, President & CEO of Iolyx Therapeutics and Chair of BIO’s Workforce Diversity, Equity, and Inclusion work group. “When leaders invest in their companies and communities, DEI pays dividends. Findings from this report illustrate that DEI is a crucial aspect of running a successful biotechnology company and it will continue to be a…